Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
about
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II studyA Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerTreatment options for small cell lung cancer - do we have more choice?Management of small-cell lung cancer: incremental changes but hope for the futurePolymeric nanoparticle technologies for oral drug delivery.Topotecan in the treatment of relapsed small cell lung cancer.Oral cancer treatment: developments in chemotherapy and beyond.Chemotherapy for small cell lung cancer: a comprehensive reviewPharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal functionPhase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeuticsSafety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.Factors affecting pharmacokinetic variability of oral topotecan: a population analysisPolymeric nanoparticle drug delivery technologies for oral delivery applications.Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo.Relapsed small cell lung cancer: treatment options and latest developments.Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancerTopotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Medical treatment of small cell lung cancer: state of the art and new development.Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.Optimal drugs for second-line treatment of patients with small-cell lung cancer.In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.Treatment update in small-cell lung cancer: from limited to extensive disease.Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.CAR-T Cell Therapy: From the Bench to the Bedside.Second-line treatments of small-cell lung cancers.Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.[Advances on treatment of limited-disease small cell lung cancer].
P2860
Q28596809-087EDD02-BF4F-4160-92C4-A875505DDC7AQ33344326-3C5B839C-E09A-4E51-8DF6-8D5C9673750AQ33391448-D1E1CCC9-CC14-4E30-ACA7-731D765E2784Q33395544-94B830B8-23F5-4954-95E7-EE55B2DB18AAQ33723735-3ADD8311-0384-4FCA-9009-FACFFC340FDEQ34013813-9DFC95EA-8227-415C-B470-7D286F3B230BQ34225096-E2DFD12E-67D7-4C70-9780-AB457B835F0AQ34363428-316D2169-4EAB-44FE-8BB9-DEA296A57DA5Q34998692-EE55FBE7-EA13-4101-91E7-FD6255A8B375Q35569379-8A06369A-D7C0-4A55-8305-8E46EF96140FQ35972223-800A7437-1232-47E7-98AA-07E26EF4E4B4Q36027042-C2DBF88F-5E54-4BB7-A599-9D45ACC3A9B8Q36663697-582BE5E6-0681-4EC3-9B75-BF9F2C836C2DQ36671493-BAF64CEB-722C-47D3-B913-55E624D4FE09Q36689071-F05074A9-1F85-48D2-8D88-AB3E45252A55Q36694409-83096FF3-C6B6-41AF-8981-0467E3501A79Q36808308-E81A3703-F210-461C-88BD-CB7B6E1B2932Q36911934-4FD1C145-F486-48D7-B5C5-5F1504E94FCEQ37321147-B9A39D1D-6AC0-4D4E-8248-94D2F8697ED3Q37362819-2D2F152C-96A8-4F6F-A0F1-B3FEC8206E6DQ37598178-934C57C7-E31E-40A2-82D1-AE108EB07251Q37709245-90B4B493-254D-4ADD-A982-923D68D5928CQ37728935-C1D8C892-6364-45C0-BCBC-1FA00701EA1CQ38082728-40B138C4-5C54-4F86-A66B-1BABDD8C622FQ38125489-1D74B989-D866-4977-B0D4-6D0185160B35Q38612645-306C2073-05D6-4D85-A140-E28F18B8EFEEQ38734204-C116B1B7-33B5-4320-B3C3-6B58E0B019AFQ39906054-BB431073-BD22-45F8-848C-68C071396DF4Q41161589-98D6E5DC-8D77-4D03-9D7F-B0EFCAF0D925Q43236440-A76D1547-6F7B-4600-8F9D-BB714EB670F8Q43939698-59075C99-7363-46D6-84DE-4BD6699BF3EFQ44837135-98C269E1-FC23-4D54-89CD-19CBDBEFF2EEQ47121638-5B7E3762-D19A-4B33-84A9-53C15AF32D35Q47789861-A64F0B13-74C3-49DA-AA8F-3A9525EB4F2BQ53740020-C6ED30A9-C6C8-415B-8CA0-5D9B967DD4B2Q55431551-FF8725E8-DC19-4713-982D-84283547503A
P2860
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Phase ii comparator study of o ...... sitive small-cell lung cancer.
@en
type
label
Phase ii comparator study of o ...... sitive small-cell lung cancer.
@en
prefLabel
Phase ii comparator study of o ...... sitive small-cell lung cancer.
@en
P2093
P1476
Phase ii comparator study of o ...... sitive small-cell lung cancer.
@en
P2093
C Steppert
G Richardson
J von Pawel
P304
P356
10.1200/JCO.2001.19.6.1743
P407
P577
2001-03-01T00:00:00Z